分子检测公司Qiagen（QIA.DE）周三宣布，瑞典收购公司EQT（EQTAB.ST）将以约96亿欧元（107.8亿美元）的价格收购其股份。
Molecular testing company Qiagen (QIA.DE) said on Wednesday Swedish buyout firm EQT (EQTAB.ST) would acquire it for about €9.6 billion ($10.78 billion).
EQT出价每股46.50欧元（52.22美元），较Qiagen上一交易日收盘价溢价8.6%。
EQT offered €46.50 ($52.22) a share for Qiagen, representing an 8.6% premium to its last close.
此次收购结束了多年来围绕这家欧洲诊断公司的收购传闻，也反映了私募股权领域对该行业的日益浓厚兴趣；随着分子检测需求的增长，相关公司已成为具有吸引力的收购目标。
The buyout ends years of takeover speculation surrounding the European diagnostics firm and reflects increasing private-equity appetite in the sector, where growing demand for molecular testing has made companies attractive acquisition targets.